Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report

Epidermal growth factor receptor (EGFR) exon 20 insertion is not associated with sensitivity to EGFR tyrosine kinase inhibitors and chemotherapy. Here, we report the case of a 41-year-old man who presented a right lower lobe nodule and mediastinal lymph node enlargement diagnosed as EGFR exon 20 ins...

Full description

Saved in:
Bibliographic Details
Published inRespiratory medicine case reports Vol. 31; p. 101236
Main Authors Matsuura, Shun, Morikawa, Keisuke, Ito, Yutaro, Kagoo, Namio, Kubota, Tsutomu, Ichijo, Koshiro, Mochizuki, Eisuke, Uehara, Masahiro, Harada, Masanori, Tsukui, Masaru, Koshimizu, Naoki
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.01.2020
Elsevier
Subjects
Case Report
Durvalumab
EGFR
Exon 20 insertion
Non-small-cell lung cancer
Non-small-cell lung cancer
Exon 20 insertion
Durvalumab
EGFR
Online AccessGet full text

Cover

More Information
Summary:Epidermal growth factor receptor (EGFR) exon 20 insertion is not associated with sensitivity to EGFR tyrosine kinase inhibitors and chemotherapy. Here, we report the case of a 41-year-old man who presented a right lower lobe nodule and mediastinal lymph node enlargement diagnosed as EGFR exon 20 insertion adenocarcinoma with high-expression programmed cell death ligand 1 (PD-L1). He showed stable disease to chemoradiation treatment at the primary tumor site. However, durvalumab treatment has good response. Non-small cell lung cancer with EGFR exon 20 insertion and high PD-L1 expression may be treated with immunotherapy exposure.
ISSN:2213-0071
2213-0071
DOI:10.1016/j.rmcr.2020.101236